Parent-to-Child Nasal Microbiota Transplant to Restore Infant Nasal Bacteria After Mupirocin Treatment for Staphylococcus Aureus Colonization

What this Trial Is About

Researchers are evaluating the impact of a nasal microbiota transplant NMT on restoring nasal microbiome diversity in infants after treatment with intranasal mupirocin for Staphylococcus aureus colonization. This study involves infants admitted to a neonatal intensive care unit who have undergone nasal decolonization and aims to understand how NMT may help reestablish healthy nasal bacteria. The trial compares different approaches a single NMT, repeated NMTs, and a placebo using sterile swabs. The transplant is done by swabbing the parents nose and then inserting the swab into the infants nose either once or multiple times, while the placebo group receives a sterile swab without microbiota. The study is randomized and conducted in parallel groups to assess the effects. Participants include infants and their parents or donors, with samples and clinical data collected at several time points after the intervention days 2, 4, 7, 10, and 14. Researchers monitor the nasal microbiome diversity in infants to evaluate engraftment and changes. Screening involves baseline assessments of both infants and donors, and infant health and hospital stay duration are tracked throughout the study, which lasts up to the primary outcome completion date.

Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment